Pragmatically, the most immediate use of IL-17 is as part of a composite monitoring strategy, alongside bleeding on probing, pocket depth, CAL, and radiographic assessment, particularly in patients with comorbid rheumatoid arthritis, diabetes, or psoriasis. This evidence concerns the gene IL17A and diabetes mellitus.